Shots:

• The first patient has been dosed in a P-II cancer vaccine trial evaluating the efficacy- tolerability & safety of BNT111 + Libtayo in combination or as monothx in 120 patients with anti-PD1 r/r unresectable Stage III or IV melanoma in EU. The company also plans to start P-II trial in 2 additional programs with BNT111 in 2021
• The 1EPs of a trial is ORR & 2EP includes ORR in monothx arms- DoR- & safety. The company holds global commercial rights to BNT111
• The P-II trial is based on previous results from a P-I Lipo-MERIT dose-escalation trial that demonstrates a favorable safety profile for BNT111 & DOR was observed in patients with melanoma who had progressed following prior checkpoint blockade

  | Ref: Globe Newswire | Image: Hindustan Times